Plasma thymic stromal lymphopoietin (TSLP) in adults with non-severe asthma: the EGEA study

Thorax. 2023 Feb;78(2):207-210. doi: 10.1136/thorax-2022-219192. Epub 2022 Dec 14.

Abstract

Thymic stromal lymphopoietin (TSLP), a cytokine involved in severe asthma treatment, was never studied in non-severe asthma.Among 969 adults from a large epidemiological study, cross-sectional analyses showed that plasma TSLP levels were associated with increased age and BMI, male sex, smoking and high TSLP levels (one IQR increase) with current asthma and poor lung function. High TSLP levels were also associated with persistence of asthma attacks (aOR=2.14 (95% CI 1.23 to 3.72)) and dyspnoea (aOR=2.71 (95% CI 1.39 to 5.28)) 10 years later.Our results suggest that TSLP could be a cytokine of interest in non-severe asthma, and its determinants of circulating levels could be considered in asthma management.

Keywords: Asthma; Asthma Epidemiology; Cytokine Biology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Asthma*
  • Cross-Sectional Studies
  • Cytokines
  • Humans
  • Lung
  • Male
  • Thymic Stromal Lymphopoietin*

Substances

  • Thymic Stromal Lymphopoietin
  • Cytokines